AZD9977   Click here for help

GtoPdb Ligand ID: 11281

Synonyms: (S)-1 [PMID: 30596500] | AZD-9977
PDB Ligand
Compound class: Synthetic organic
Comment: AZD9977 is a selective, nonsteroidal, mineralocorticoid receptor modulator [1-3]. It acts as a partial antagonist, but is equally as efficacious as eplerenone in organ protection in a rat model of cardio-renal disease.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 96.97
Molecular weight 399.12
XLogP 1
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CNC(=O)C[C@H]1COc2c(N1C(=O)c1ccc3c(c1)NC(=O)CO3)ccc(c2)F
Isomeric SMILES CNC(=O)C[C@H]1COc2c(N1C(=O)c1ccc3c(c1)NC(=O)CO3)ccc(c2)F
InChI InChI=1S/C20H18FN3O5/c1-22-18(25)8-13-9-28-17-7-12(21)3-4-15(17)24(13)20(27)11-2-5-16-14(6-11)23-19(26)10-29-16/h2-7,13H,8-10H2,1H3,(H,22,25)(H,23,26)/t13-/m0/s1
InChI Key MBKYLPOPYYLTNW-ZDUSSCGKSA-N
No information available.
Summary of Clinical Use Click here for help
AZD9977 is a clinical candidate for heart failure treatment.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03682497 Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium Phase 1 Interventional AstraZeneca This study was terminated in response to the COVID-19 pandemic, as it was deemed to risky to bring trial participants to test sites.
NCT03435276 Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects Phase 1 Interventional AstraZeneca 4